Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00646581 · ClinicalTrials.gov registry record · Phase 4
Effect of Single Dose Intranasal Insulin On Cognitive Function
A Phase 4 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00646581 is a Phase 4 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 30 participants.
The verdict
NCT00646581, a Phase 4 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The investigators propose a single dose, double-blinded, placebo-controlled trial of intranasal insulin in 40 subjects with schizophrenia or schizoaffective disorder to examine insulin's effect on cognition. The specific aims include: 1. Examine the effects of single doses of 40 IU intranasal insulin compared to placebo on cognitive functioning, including attention and memory. 2. Examine whether single dose of intranasal insulin administration will raise serum insulin level and decrease plasma glucose level Insulin will be delivered through an air spray pump into your nose. The investigators will be comparing one dose of insulin (40 International Units) with placebo, an inactive liquid.
Interventions
- DRUG Placebo
- DRUG Insulin (Humulin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00646581
The ClinicalTrials.gov registry entry for NCT00646581 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00646581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00646581 about?
NCT00646581 is a clinical study titled "Effect of Single Dose Intranasal Insulin On Cognitive Function". The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders. Insulin is not being used to treat diabetes in this study. The investigators propose a...
What is the current status of trial NCT00646581?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2006-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00646581?
The interventions under investigation include: Placebo (DRUG), Insulin (Humulin) (DRUG).
Who is sponsoring clinical trial NCT00646581?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.